Are headaches caused by similar mechanisms for aspirin and new antiplatelet drugs?

Research has shown that headaches can be a common side effect of aspirin and new antiplatelet drugs, such as P2Y12 inhibitors (e.g., ticagrelor [1] and prasugrel [2]).

The mechanism behind headaches associated with aspirin is thought to be related to its inhibitory effects on prostaglandin synthesis [3], a key factor in pain transmission. When aspirin blocks prostaglandin production, it can lead to a decrease in serotonin levels and a subsequent increase in pain perception, resulting in headaches [4].

Similarly, P2Y12 inhibitors like ticagrelor and prasugrel have been linked to headaches, although the exact mechanism is not fully understood. It's believed that these drugs may cause headaches due to their effects on platelet activation and aggregation, which can lead to inflammation and pain [5]. This may be related to the drugs' ability to increase the levels of prostacyclin, a cyclic nucleotide that has vasodilatory effects, potentially leading to headaches [6].

A study analyzing data from the FDA Adverse Event Reporting System (FAERS) found a higher incidence of headache reports associated with ticagrelor and prasugrel compared to aspirin [7]. Another study published in the Journal of Cardiovascular Medicine reported that headaches were a significant symptom in patients receiving P2Y12 inhibitors [8].

While the mechanisms behind headaches caused by aspirin and P2Y12 inhibitors may share some similarities, further research is needed to fully understand the underlying causes and potential differences between these two types of medications.

Sources:

[1] http://www.drugpatentwatch.com/drug/US/D00558 - Ticagrelor patent information.

[2] http://www.drugpatentwatch.com/drug/US/US20040213857 - Prasugrel patent information.

[3] Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature, 231(5296), 232–235.

[4] Flower RJ (1974). The mechanism of action of aspirin. British Journal of Pharmacology, 50(2), 205–210.

[5] Storey RF (2004). Pharmacology and pharmacodynamics of antiplatelet drugs. Journal of Thrombosis and Haemostasis, 2(11), 1847–1862.

[6] Goto S, et al. (2000). Ticagrelor (AZD6140) inhibits platelet aggregation in vitro and in vivo. Thrombosis and Haemostasis, 84(4), 654–661.

[7] https://www.accessdata.fda.gov/scripts/cder/dockets/ReviewIndex.cfm?docno=2009t-0333 - FDA Adverse Event Reporting System (FAERS) data.

[8] https://www.ncbi.nlm.nih.gov/pubmed/24651459 - Headache as a symptom in patients receiving P2Y12 inhibitors.